Regorafenib (CAS No: 755037-03-7, chemical name 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide) is a potent, oral multi-kinase inhibitor. It plays a decisive role in modern targeted oncology therapies by suppressing a broad spectrum of receptor tyrosine kinases (RTKs) involved in tumor angiogenesis (VEGFR1, VEGFR2, VEGFR3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR-β, FGFR1).
As global pharmaceutical manufacturing transitions toward second- and third-line targeted treatments, securing a dependable, ultra-high-purity supply of Regorafenib API has become a imperative priority for generic drug developers, clinical research organizations (CROs), and commercial finished dosage form (FDF) manufacturers. The complexity of Regorafenib's fluorinated structure requires precise multi-step synthesis, strict polymorphic control (specifically Polymorph Form I), and rigid suppression of genotoxic impurities.
Our advanced cGMP synthesis process guarantees organic impurities < 0.10%, individual unspecified impurities < 0.05%, and heavy metals compliant with ICH Q3D elemental impurity limits, ensuring smooth global DMF submissions.
The oncology API landscape is undergoing significant market shifts driven by expiring patent barriers, expanding indications, and rising demand in emerging markets. Understanding these macro trends is vital for pharmaceutical sourcing executives and formulation scientists.
Originally approved for refractory metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST), Regorafenib has established a stronghold as a standard-of-care second-line therapeutic for advanced hepatocellular carcinoma (HCC). Ongoing clinical trials evaluating combination therapies with immune checkpoint inhibitors (PD-1/PD-L1) are driving sustained demand growth globally.
With patent expirations approaching across major therapeutic regions, generic drug sponsors are rapidly initiating ANDA (Abbreviated New Drug Application) submissions. Early sourcing of high-grade Regorafenib active ingredient with complete technical documentation (US DMF, CEP, EU CTD Module 3) provides significant first-to-market commercial leverage.
Modern pharmaceutical supply chains require chemical suppliers to transition from legacy batch reaction kettles to continuous flow synthesis and continuous micro-crystallization. This minimizes heat accumulation risks in fluorination steps and yields stable, uniform polymorph crystal sizes ideal for direct compression tablets.
Procurement directors and quality assurance managers face strict scrutiny when selecting an API manufacturing partner for high-potency oral solid dosages. Below is how our strategic manufacturing framework systematically resolves critical procurement pain points:
Regorafenib exhibits polymorphic diversity. Polymorph Form I is the thermodynamically stable, bioavailable crystalline state required for equivalent dissolution profiles in finished tablet forms. Our controlled crystallization technology guarantees 100% polymorphic phase purity verified via X-Ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) for every batch.
During the coupling reaction of 4-chloro-3-(trifluoromethyl)phenyl isocyanate and 4-(4-amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, trace aromatic amine intermediates can persist. We utilize specialized liquid chromatography-mass spectrometry (LC-MS/MS) analytical protocols to ensure residual genotoxic impurities remain far below the Threshold of Toxicological Concern (TTC) level (<1.5 µg/day).
Fluctuations in raw material precursors like 4-amino-3-fluorophenol can disrupt production schedules. Operating from an standard chemical production zone spanning 250,000 square meters, our dual-sourcing model for key starting materials (KSMs) guarantees uninterrupted multi-ton annual manufacturing capability.
Speed-to-market requires fully audited, compliant documentation. We supply full CTD Module 3 filing support, complete stability study data under ICH Q1A(R2) conditions (accelerated, long-term, and stress testing), and immediate access to DMF reference letters to accelerate client regulatory approvals.
Our commitment to engineering excellence ensures that every batch of Regorafenib matches stringent clinical requirements. Below is an overview of our analytical and chemical synthesis roadmap:
Precision reduction of nitro-aromatic precursors utilizing eco-friendly precious metal catalysts, achieving >99.5% chemical conversion with zero heavy-metal carryover in raw crude intermediate streams.
Environmentally controlled reaction conditions eliminating side-reaction bi-products (such as symmetrical urea impurities), maintaining stoichiometric conversion for high-yield synthesis.
Process Analytical Technology (PAT) employing inline Focused Beam Reflectance Measurement (FBRM) to control nucleation rate, crystal growth dynamics, and particle size distribution (d90 < 20 µm).
Full spectrum release testing including UHPLC purity assay, GC-MS residual solvent screening (ICH Q3C), Karl Fischer moisture analysis, ICP-MS elemental analysis, and particle size laser diffraction.
Gentolex’s core objective is creating global opportunities by connecting worldwide pharmaceutical clients with reliable, high-grade products and localized support. Up to date, Gentolex Group has established strong partnerships across more than 10 countries, featuring dedicated regional representatives in key hubs including Mexico and South Africa.
Our operational framework extends beyond standard raw material supply to encompass comprehensive life-science services:
Every facility operating under the Gentolex banner aligns with international cGMP regulatory frameworks. We maintain rigorous compliance across ISO 9001:2015, ISO 14001:2015 environmental standards, and ICH Q7 guidelines for active pharmaceutical ingredients.
Our local support teams in North America, Latin America, Europe, and Africa streamline customs clearance, provide local-currency transaction support, and ensure quick deployment of technical dossiers for local health authority audits (such as US FDA, EMA, ANVISA, and SAHPRA).
As the pharmaceutical industry advances toward greener, more efficient chemical synthesis, our R&D engineering division is actively pursuing technical innovations for targeted kinase inhibitors like Regorafenib:
Developing eco-friendly continuous catalysis systems that eliminate toxic organic solvents in favor of recyclable green reaction media, reducing VOC emissions by over 45% during mass production runs.
Implementing supercritical fluid crystallization (SFC) techniques to produce sub-micron particle sizes, increasing oral bioavailability and enabling reduced active dose requirements in next-generation clinical formulations.
Exploring specialized intermediate derivatives for antibody-drug conjugate (ADC) payloads and dual-target kinase inhibitor constructs, broadening the clinical horizons for targeted oncology treatments.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
With an overall factory construction area of 250,000 square meters under international standard, we offer flexible, scalable and cost-effective solutions for clients worldwide.
